COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ DE PRESSE
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Bioxytran, Inc. announces positive results from Phase 1b/2a clinical study evaluating oral ProLectin-M in COVID-19 patients, showing earlier viral clearance, clinical improvement, and safety -
-
-
COMMUNIQUÉ DE PRESSE
Vusion - Information relating to the total number of voting rights and shares making up the share capital
VusionGroup's voting rights and share capital as of February 28, 2026 revealed; Vusion leads in AI-powered solutions for global retail groups, focusing on sustainable and innovative Connected Commerce -
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares from February 23 to February 27, 2026
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 23 au 27 février 2026
-
COMMUNIQUÉ DE PRESSE
Huawei Releases the Fully Connected Industrial Networks Report, Aiming to Promote the Upgrade of Smart Factory Architecture
Huawei releases the Fully Connected Industrial Networks report during MWC Barcelona 2026, highlighting trends in industrial networks and showcasing smart factory solutions -
COMMUNIQUÉ DE PRESSE
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Skyhawk Therapeutics announces that Australia's Therapeutic Goods Administration has determined SKY-0515 for Huntington's Disease meets eligibility criteria for provisional registration pathway
